Oncology Analytics, a Plantation, FL-based technology-enabled service company which provides health plans, providers and patients with an evidence-based, analytics focused approach to utilization management that is purpose-built for oncology, closed $21m in Series B funding.
The round was led by Oak HC/FT joined by new investor McKesson Ventures along with returning investors Blue Cross Blue Shield Venture Partners and Sandbox Advantage Fund.
The company intends to use the funds to expand its oncology benefits management capabilities and accelerate strategic investments in data analytics, data science, and innovative digital health technologies.
The company also announced that leading healthcare investor Annie Lamont, managing partner, Oak HC/FT along with renowned bioethicist and oncologist Ezekiel J. “Zeke” Emanuel, M.D. Ph.D., Venture Partner, Oak HC/FT will join Oncology Analytics’ Board of Directors.
Led by Rick Dean, CEO, Oncology Analytics provides health plans, providers and patients with an evidence-based, technology-driven approach to utilization management, which is purpose-built for oncology. Used by physicians to support over 3.5 million health plan members in the US and Puerto Rico, the company’s e-Prior Authorization platform is updated daily to accurately reflect more than 6,000 oncology treatment protocols for anti-cancer treatment across all cancer types and stages, including chemotherapy, radiation therapy, precision medicine, targeted therapy, and supportive care.